Table 2.
Distribution of benign and malignant entities in 110 conjunctival lesions as per the WHO categorization based on gender and the age group
| WHO lesion category | All (n = 110) n (%) | Gender | Benign (n = 100) | Malignant (n = 10) | |||
|---|---|---|---|---|---|---|---|
| Males (n = 67) n (%) | Females (n = 43) n (%) | Children ≤ 16 y (Total n = 18) n (%) | Adults > 16 y (Total n = 92) n (%) | Children ≤ 16 y (Total n = 18) n (%) | Adults > 16 y (Total n = 92) n (%) | ||
| Fibro-degenerative / Proliferative | 59 (53.6) | 42 (62.7) | 17 (39.5) (42/59 (71.2%) vs. 17/59 (28.8%) p < 0.001*) | 3 (16.7) | 56 (60.9) | 0 (0.0) | 0 (0.0) |
| Melanocytic Lesions | 15 (13.6) | 7 (10.4) | 8 (18.6) | 6 (33.3) | 8 (8.7) | 0 (0.0) | 1 (1.1) |
| Inflammatory | 10 (9.1) | 5 (7.5) | 5 (11.6) | 0 (0.0) | 10 (10.9) | NA | NA |
| Epithelial Lesions | 8 (7.3) | 6 (9.0) | 2 (4.7) | 0 (0.0) | 2 (2.0) | 0 (0.0) | 6 (6.5) |
| Hematolymphoid Lesions | 7 (6.4) | 3 (4.5) | 4 (9.3) | 3 (16.7) | 0 (0.0) | 0 (0.0) | 4 (4.3) |
| Tumor-like lesions | 6 (5.5) | 3 (4.5) | 3 (7.0) | 3 (16.7) | 3 (3.3) | NA | NA |
| Hamartoma & Choristoma | 3 (2.7) | 1 (1.5) | 2 (4.7) | 3 (16.7) | 0 (0.0) | NA | NA |
| Vascular Lesions | 2 (1.8) | 0 (0.0) | 2 (4.7) | 0 (0.0) | 2 (2.2) | 0 (0.0) | 0 (0.0) |
WHO World Health Organization
*Statistically significant at 5% level of significance
NA not applicable; Y years